Dr. Mohammad Jahanzeb

  • Medical Oncologist
  • Spoken languages English


Dr. Mohammad Jahanzeb (FACP, FASCO) is the Chief Medical Oncology Scientific and Strategic Advisor at GenesisCare. Dr. Jahanzeb was previously a Professor of Clinical Medicine at the University of Miami’s Miller School of Medicine and served as the Medical Director of the University of Miami’s Sylvester Deerfield campus. An international lecturer on complex issues related to breast and lung cancers, Dr. Jahanzeb has given more than 900 lectures as an invited speaker and has authored or contributed to more than 200 original reports, books, reviews and abstracts. He has been the Chair of the FLASCO Continuing Medical Education Committee for three years and served on the Board of Directors and the Expert Panels for Lung Cancer and Breast Cancer of the National Comprehensive Care Network between 2003 and 2013.

Career Positions

Current position(s)

  • GenesisCare - Chief Medical Oncology Scientific and Strategic Advisor, Boca Raton, FL

Past position(s)

  • Sylvester Comprehensive Cancer Center - Professor of Clinical Medicine, Hematology-Oncology, Deerfield Beach, FL
  • Sylvester Comprehensive Cancer Center - Medical Director, Deerfield Beach, FL
  • Sylvester Comprehensive Cancer Center - Volunteer Assistant Professor, Deerfield Beach, FL
  • Lynn Comprehensive Cancer Center - Medical Director, West, Boca Raton, FL
  • University of Tennessee College of Medicine - Chief -·Division of Hematology/Oncology, Memphis, TN
  • University of Tennessee - Fellowship Program Director Hematology Oncology Division, Memphis, TN



  • King Edward Medical College, University of Punjab, MD, Medicine, Lahore, Pakistan


  • The University of Connecticut, Internal Medicine, Mansfield, CT


  • Washington University in St. Louis, Hematology and Oncology, St. Louis, MO

Expertise And Interests


  • Cancers of the breast and lung.


Awards and honors

  • Castle Connolly Top Doctors in America 2010-2016Best Doctors in America 2007-2008, 2011Castle Connolly Medical Best Doctors in America 2006Gold Medal Award KEMCAANA 2006NCCN Board of Producers Award 2008Silver Medal in Final Professional M.B.B.S. (MD)Nati


  • Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review.

Clinical studies

Primary Objective • To assess whether ALK kinase domain mutations (G1202/C1156Y /I1171/L1196/ V1180/ F1174/ compound mutation) associated with drug resistance are prognostic for objective response to subsequent ALK inhibitor therapy. • To assess whether subsequent pemetrexed based chemotherapy improves objective response comparing to ALK inhibitor therapy for no ALK mutation patients • To evaluate objective responses of patients with specific genetic alterations (ALKL1198F/MET double mutation or high-level MET gene amplification) treated with crizotinib.

View Study

Mohammad Jahanzeb's Reviews


based on 57 Ratings 15 Comments


Honestly I can't think of a thing.


Given me written information to review on the treatment course or plan suggested.


It was a perfect experience. Thank you!


She was very clear with everything, informing me about where were at what we're to do Hopefully where we going I think he did everything quite well, so I don't have any negative feedback at all. Thank you very much actually.

Read More

Ratings and Comments Powered by NRC Health